Fulltext

Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group

Herbrecht, Raoul ; Patterson, Thomas F. ; Slavin, Monica A. ; Marchetti, Oscar ; Maertens, Johan ; Johnson, Elizabeth M. ; Schlamm, Haran T. ; Donnelly, J. Peter ; Pappas, Peter G.

In: Clinical Infectious Diseases, 2015, vol. 60, no. 5, p. 713-720

Ajouter à la liste personnelle
    Titre
    • Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group
    Auteur
    • Herbrecht, Raoul. Department of Oncology and Hematology, Hôpital de Hautepierre and Université de Strasbourg, France
    • Patterson, Thomas F.. University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio
    • Slavin, Monica A.. Peter MacCallum Cancer Center and University of Melbourne, Australia
    • Marchetti, Oscar. Infectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV), Switzerland
    • Maertens, Johan. Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, KU Leuven, Belgium
    • Johnson, Elizabeth M.. Public Health England Mycology Reference Laboratory and National Collection of Pathogenic Fungi, Bristol, United Kingdom
    • Schlamm, Haran T.. Pfizer Global Research and Development, New York, New York
    • Donnelly, J. Peter. Radboud University Medical Center, Nijmegen, The Netherlands
    • Pappas, Peter G.. Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Clinical Infectious Diseases, 2015, vol. 60, no. 5, p. 713-720. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:304381
    Summary
    Episodes of invasive aspergillosis (IA) recruited to the voriconazole trial were reclassified according to the revised EORTC/MSG definitions. The efficacy of voriconazole was confirmed for possible, probable, and proven IA and was still better than found for the comparator arm